Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H I - J - K - L - M N - O - P - Q - R - S T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter V

GENERIC NAME

TRADE NAME

CONDITION

STUDY CODE

STUDY NAME

ACCESS TO STUDY / PROTOCOL

ACCESS TO RESULTS

VALPROATE

Depakine

Bipolar Disorder

DPKOT_L_01567

GEVANS

NCT00477373

VALPROATE

Depakine

Epilepsy

L_8923

NA

NA

VALPROATE

Depakine

Epilepsy

L_8971

VAPOP

NCT00385411

VALPROATE

Depakine

Bipolar Disorder

L_8979

NA

NA

VALPROATE

Depakine

Bipolar Disorder

L_9387

NA

NCT00431522

VALPROATE

Depakine

Bipolar disorder

L_9524

ADOKOT

NCT00271258

VALPROATE

Depakine

Epilepsy

L_9557

CIVET

NA

VALPROATE

Depakine

Bipolar Disorder

R_8740

VALID

NCT00264173

VALPROATE

Depakine

Bipolar I Disorder

EFC_5196

NEW DELI

NA

VALPROATE

Caprelsa

Thyroid Cancer

D4200C00008 
(LPS14954)

NA

NA

NCT00098345

VALPROATE

Caprelsa

Colorectal Cancer

D4200C00047
(LPS15025)

NA

NA

NCT00500292

VALPROATE

Caprelsa

Non Small Cell Lung Cancer

D4200C00057

NA

NA

NCT00364351

VANDETANIB

Caprelsa

Cancer of Ovary, Fallopian Tube, or Peritoneum

D4200C00083

ZACFAST

NCT00862836

VANDETANIB

Caprelsa

Biliary Tract Cancer

D4200L00007

VANGOGH

NCT00753675

VANDETANIB

Caprelsa

Prostate Cancer

D4200C00080

NA

NCT00659438

VANDETANIB

Caprelsa

Lung Cancer

D4200C00036

ZEAl

NCT00418886

VANDETANIB

Caprelsa

Lung Cancer

D4200C00077

NA

NCT00777179

VANDETANIB

Caprelsa

Mesothelioma

D4200C00075

NA

NCT00597116

VANDETANIB

Caprelsa

Thyroid Cancer

D4200C00068

NA

NCT00358956

VANDETANIB

Caprelsa

Prostate Cancer

D4200C00055

NA

NCT00498797

VANDETANIB

Caprelsa

Colorectal Cancer

D4200C00048

NA

NCT00454116

VANDETANIB

Caprelsa

Breast Cancer

D4200C00046

NA

NCT00494481

VANDETANIB

Caprelsa

Breast Cancer

D4200C00045

NA

EudraCT: 2005-003591-38

VANDETANIB

Caprelsa

Lung Cancer

D4200C00044

NA

NCT00404924

VANDETANIB

Caprelsa

Lung Cancer

D4200C00032

ZODIAC

NCT00312377

VANDETANIB

Caprelsa

Thyroid Cancer

D4200C00098

NA

NCT01661179

VANDETANIB

Caprelsa

Thyroid Cancer

LPS14809

NA

NCT01496313

VANDETANIB

Caprelsa

Thyroid Cancer

LPS14940

NA

NCT00537095

VANDETANIB

Caprelsa

Liver Cancer

D4200C00072

NA

NCT00508001

VANDETANIB

Caprelsa

Breast Cancer

D4200L00009

ZACFAST

NCT00752986

VANDETANIB

Caprelsa

Prostate Cancer

D4200L00010

ZENITH

NCT00686036

VANDETANIB

Caprelsa

Prostate Cancer

LPS14813

NA

NCT01876784

VANDETANIB

Caprelsa

Lung Cancer

D4200L00012

ZELIG

NCT00753714

VANDETANIB

Caprelsa

Medullary Thyroid Cancer

D4200C00088

NA

NCT01298323

VENGLUSTAT

Not marketed

Fabry Disease

ACT13739

NA

EudraCT: 2013-005324-41

VENGLUSTAT

Not marketed

Parkinson's Disease

ACT14820

MOVES-PD

NCT02906020

VENGLUSTAT

Not marketed

Fabry Disease

LTS14116

NA

NCT02489344

VENGLUSTAT

Not marketed

Congenital cystic kidney disease

LTS15823

NA

NCT04705051

VENGLUSTAT

Not marketed

Polycystic kidney, autosomal dominant

EFC15392

STAGED-PKD

NCT03523728

VIGABATRIN

Sabril

Infantile Spasms

EFC12369

NA

EudraCT: 2017-000230-62

VIGABATRIN

Sabril

Infantile Spasms

LTS12745

NA

EudraCT: 2017-000611-17

 

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted